tiprankstipranks
TipRanksStock Market NewsSLP NewsOppenheimer Thinks Simulations Plus’ Stock is Going to Recover
Blurbs

Oppenheimer Thinks Simulations Plus’ Stock is Going to Recover

Oppenheimer analyst Francois Brisebois reiterated a Buy rating on Simulations Plus (SLPResearch Report) today and set a price target of $75.00. The company’s shares closed last Thursday at $45.88, close to its 52-week low of $36.90.

According to TipRanks.com, Brisebois is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -15.2% and a 23.8% success rate. Brisebois covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Avadel Pharmaceuticals, and Diamedica Therapeutics.

Simulations Plus has an analyst consensus of Moderate Buy, with a price target consensus of $61.00.

See the top stocks recommended by analysts >>

Simulations Plus’ market cap is currently $925.3M and has a P/E ratio of 97.62.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Simulations Plus, Inc. engages in licensing and conducting drug research by pharmaceutical and biotechnology companies. It offers pharmaceutical, and chemical, cosmetics and food industries. The company was founded by Walter S. Woltosz and Virginia E. Woltosz on July 17, 1996 and is headquartered Lancaster, CA.

Read More on SLP:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More